CS MEDICA A/S Secures Repurchase Orders from Key European Partners

CANNORDIC Continues Momentum with Recurring Orders of 45.000 Units from European Healthcare Leaders

CS MEDICA, a pioneering MedTech company specializing in pain management and autoimmune diseases with innovative substance-based medical devices containing bioactive CBD, announces that its subsidiary, CANNORDIC, has received repurchase orders for 45,000 units from its German partner, Alsitan, and Spanish partner, Uriach, for delivery in Q3 and Q4, 2024.

CANNORDIC hereby strengthens its market penetration with a total of 241,000 units in orders from the two leading European Healthcare Partners, with Alsitan placing its sixth order and Uriach placing its third order.

It marks a significant step in reinforcing CANNORDIC's presence in the global market for innovative substance-based medical devices with bioactive CBD aimed at pain relief and autoimmune diseases.

These recurring orders reflect our partners' trust in our products and underscore their success in local markets, supporting our continued growth in the healthcare sector, says Lone Henriksen, CEO of CS MEDICA.